Literature DB >> 28425837

Calprotectin levels in rheumatoid arthritis and their correlation with disease activity: a meta-analysis.

Sang-Cheol Bae1, Young Ho Lee1,2.   

Abstract

OBJECTIVE: We evaluated the relationship between calprotectin levels and rheumatoid arthritis (RA), and the correlation between plasma/serum calprotectin and RA activity.
METHODS: We searched PUBMED, EMBASE, and Cochrane databases and performed meta-analyses comparing plasma/serum or synovial fluid calprotectin levels in RA patients and controls, and correlation coefficients between calprotectin levels and disease activity for 28 joints (DAS28) as well as C-reactive protein (CRP) in RA patients.
RESULTS: Sixteen studies including 849 RA patients and 266 controls were available for meta-analysis. Meta-analysis showed that calprotectin levels were significantly higher in the RA group than in the control group (SMD = 2.337, 95% CI = 1.544-3.130, p < 1.0 × 10-8). Stratification by rheumatoid factor (RF) status revealed significantly elevated calprotectin levels in the RF-positive RA group compared to that of the RF-negative RA group (SMD = 0.574, 95% CI = 0.345-0.804, p = 9.2 × 10-7). Meta-analysis of correlation coefficients identified a significant positive correlation between calprotectin levels and CRP or DAS28 (correlation coefficient for CRP = 0.566, 95% CI = 0.512-0.615, p < 1.0 × 10-8; correlation coefficient for DAS28 = 0.438, 95% CI = 0.269-0.518, p = 2.5 × 10-6). Calprotectin levels in synovial fluid were significantly higher in the RA group than in the control group (SMD = 2.891, 95% CI = 1.067-4.715, p = 0.002).
CONCLUSIONS: Our meta-analysis demonstrates that circulating and synovial fluid calprotectin levels are high in patients with RA, and that circulating calprotectin levels positively correlate with RA activity.

Entities:  

Keywords:  Calprotectin; activity; rheumatoid arthritis

Mesh:

Substances:

Year:  2017        PMID: 28425837     DOI: 10.1080/00325481.2017.1319729

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  9 in total

1.  Myeloperoxidase and calprotectin; Any role as non-invasive markers for the prediction of ınflammation and fibrosis in non-alcoholic steatohepatitis?

Authors:  Ercan Bıçakçı; Coşkun Özer Demirtaş; Çiğdem Çelikel; Goncagül Haklar; Deniz Güney Duman
Journal:  Turk J Gastroenterol       Date:  2020-10       Impact factor: 1.852

2.  Use of prognostic factors of rheumatoid arthritis in clinical practice and perception of their predictive capacity before and after exposure to evidence.

Authors:  Santiago Muñoz-Fernández; Teresa Otón-Sánchez; Loreto Carmona; Jaime Calvo-Alén; Alejandro Escudero; Javier Narváez; Jose Manuel Rodríguez Heredia; Susana Romero Yuste; Paloma Vela; Sara Luján Valdés; Ana Royo García; José Luis Baquero
Journal:  Rheumatol Int       Date:  2018-09-24       Impact factor: 2.631

3.  Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis.

Authors:  Lieke Tweehuysen; Nathan den Broeder; Noortje van Herwaarden; Leo A B Joosten; Peter L van Lent; Thomas Vogl; Frank H J van den Hoogen; Rogier M Thurlings; Alfons A den Broeder
Journal:  RMD Open       Date:  2018-04-09

Review 4.  The Role of Calprotectin in Rheumatoid Arthritis.

Authors:  Qin Wang; Weiqian Chen; Jin Lin
Journal:  J Transl Int Med       Date:  2019-12-31

5.  Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs.

Authors:  Emma C de Moel; Jürgen Rech; Michael Mahler; Johannes Roth; Thomas Vogl; Anne Schouffoer; Robbert J Goekoop; Tom W J Huizinga; Cornelia F Allaart; René E M Toes; Georg Schett; Diane van der Woude
Journal:  Arthritis Res Ther       Date:  2019-12-05       Impact factor: 5.156

6.  Circulating Calprotectin as a Biomarker of COVID-19 Severity.

Authors:  Michael Mahler; Pier-Luigi Meroni; Maria Infantino; Katherine A Buhler; Marvin J Fritzler
Journal:  Expert Rev Clin Immunol       Date:  2021-04-13       Impact factor: 4.473

7.  Serum Calprotectin Level Is Independently Associated With Carotid Plaque Presence in Patients With Psoriatic Arthritis.

Authors:  Isaac T Cheng; Huan Meng; Martin Li; Edmund K Li; Priscilla C Wong; Jack Lee; Bryan P Yan; Alex P W Lee; Ho So; Lai-Shan Tam
Journal:  Front Med (Lausanne)       Date:  2022-07-08

8.  Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis.

Authors:  Matthias Jarlborg; Delphine S Courvoisier; Céline Lamacchia; Laura Martinez Prat; Michael Mahler; Chelsea Bentow; Axel Finckh; Cem Gabay; Michael J Nissen
Journal:  Arthritis Res Ther       Date:  2020-05-06       Impact factor: 5.156

Review 9.  Contribution of Multiplex Immunoassays to Rheumatoid Arthritis Management: From Biomarker Discovery to Personalized Medicine.

Authors:  Carlos M Laborde; Patricia Castro-Santos; Roberto Díaz-Peña
Journal:  J Pers Med       Date:  2020-10-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.